RecruitingNCT07484217
Solriamfetol for daytime sleepiness with depression
About this title
Read the official source — NCT07484217Medication studyAges 18–65United States
Understand this study
Who could participate?
This study is for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
What will I do during this study?
This study has an open-label solriamfetol treatment period followed by a randomized withdrawal phase for participants who respond. Responders are assigned to continue solriamfetol or switch to placebo (an inactive comparison treatment); screening and follow-up assessments are also part of the study.
- Listed locations
- Tucson and 39 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: February 23, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 508
- Sponsor
- Axsome Therapeutics, Inc.
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT07484217
- Official title
Show the full official title
A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal Study of Solriamfetol in Subjects With Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Tucson · Bellflower · Chino
33 more locations
- Glendale
- Imperial
- Los Angeles
- Oceanside
- Redlands
- San Diego
- Sherman Oaks
- Walnut Creek
- Jacksonville
- Miami
- Atlanta
- Norcross
- Snellville
- Chicago
- Pikesville
- Springfield
- Las Vegas
- Cherry Hill
- Toms River
- Brooklyn
- New York
- Staten Island
- The Bronx
- Cincinnati
- Edmond
- Oklahoma City
- Portland
- Memphis
- Austin
- Bellaire
- Dallas
- Houston
- San Antonio
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Axsome Therapeutics, Inc.
Does this study involve medication?
Yes. The study involves medication, including Solriamfetol 150 MG and Placebo.
Who can participate?
This study is for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
